NASDAQ:ALLKAllakos Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allakos Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $72.00 +4.40 (+6.51 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$66.78Now: $72.00▼$72.7950-Day Range$62.75MA: $70.87▼$80.6952-Week Range$30.32Now: $72.00▼$139.99Volume292,257 shsAverage Volume318,079 shsMarket Capitalization$3.51 billionP/E RatioN/ADividend YieldN/ABeta1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.00, Allakos has a potential downside of 9.7% from its current price of $72.00.Amount of Analyst CoverageAllakos has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesAllakos has received 149 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllakos has received 179 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllakos has received 54.57% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allakos and other stocks. Vote “Outperform” if you believe ALLK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALLK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,277,669.00 in company stock.Percentage Held by Insiders44.77% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.40% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to decrease in the coming year, from ($2.58) to ($3.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -36.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -36.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.06 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK Previous Symbol CUSIPN/A CIKN/A Webwww.allakos.com Phone650-597-5002Debt Debt-to-Equity RatioN/A Current Ratio33.75 Quick Ratio33.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book7.07Profitability EPS (Most Recent Fiscal Year)($1.89) Net Income$-85,370,000.00 Net MarginsN/A Return on Equity-22.74% Return on Assets-21.66%Miscellaneous Employees62 Outstanding Shares48,770,000Market Cap$3.51 billion Next Earnings Date8/3/2020 (Estimated) OptionableNot Optionable NASDAQ:ALLK Rates by TradingView Receive ALLK News and Ratings via Email Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Allakos (NASDAQ:ALLK) Frequently Asked Questions How has Allakos' stock been impacted by COVID-19 (Coronavirus)? Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLK stock has increased by 23.5% and is now trading at $72.00. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Allakos? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allakos. When is Allakos' next earnings date? Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Allakos. How were Allakos' earnings last quarter? Allakos Inc (NASDAQ:ALLK) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.01. View Allakos' earnings history. What price target have analysts set for ALLK? 3 Wall Street analysts have issued twelve-month target prices for Allakos' shares. Their forecasts range from $36.00 to $94.00. On average, they expect Allakos' stock price to reach $65.00 in the next twelve months. This suggests that the stock has a possible downside of 9.7%. View analysts' price targets for Allakos. Has Allakos been receiving favorable news coverage? Press coverage about ALLK stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allakos earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Allakos. Are investors shorting Allakos? Allakos saw a drop in short interest in June. As of June 15th, there was short interest totaling 6,820,000 shares, a drop of 7.3% from the May 31st total of 7,360,000 shares. Based on an average daily trading volume, of 354,600 shares, the short-interest ratio is currently 19.2 days. Currently, 27.3% of the shares of the stock are sold short. View Allakos' Current Options Chain. Who are some of Allakos' key competitors? Some companies that are related to Allakos include Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Ascendis Pharma A/S (ASND) and Autolus Therapeutics (AUTL). Who are Allakos' key executives? Allakos' management team includes the following people: Dr. Robert Alexander, Pres, CEO & Director (Age 49)Dr. Adam L. Tomasi, CFO, COO & Sec. (Age 49)Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 60)Dr. Ruby Casareno Ph.D., VP of Technical OperationsMr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 56) When did Allakos IPO? (ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. What is Allakos' stock symbol? Allakos trades on the NASDAQ under the ticker symbol "ALLK." How do I buy shares of Allakos? Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $72.00. How big of a company is Allakos? Allakos has a market capitalization of $3.51 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe. What is Allakos' official website? The official website for Allakos is www.allakos.com. How can I contact Allakos? Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
